Rockwell Medical Reports Third-Quarter Results as Revenue Figures Remain Unverified
Key Facts
Rockwell Medical said it will release results for the third quarter ended September 30, 2026, on November 12, after financial results figures could not be verified on a reliable public page. The company had scheduled a live webcast to discuss the results at 8:00 a.m. Eastern Time. Revenue, earnings per share and whether results exceeded analyst estimates therefore cannot be confirmed in this report. The results put the company’s operating performance under scrutiny as it has announced an agreement to acquire Vantive’s global kidney dialysis products and equipment business. The latest available closing price before the results reflects the stock’s movement in prior sessions, not a subsequent response to the announcement.
In the latest completed session before the results release, RMTI closed at $7.08 on November 11, 2026. It had closed at $7.31 on November 10, $7.52 on November 9 and $7.73 on November 6. It also closed at $7.60 on November 5. These prices provide context for the stock’s movement before the announced results date, but do not represent a market reaction to the results. The available data do not include a verified share price after the results were released.
The latest available operating comparison dates to the second quarter of 2026, when net sales were $17.8 million, up 11% year over year from $16.1 million in the second quarter of 2025. The company attributed the increase to additional sales to new customers in the western United States and larger purchases by existing customers. Gross profit rose to $3.2 million from $2.5 million a year earlier, an increase of 30%. Gross margin also widened to 18% from 16% in the comparable period. The company said the improvement in margin was primarily related to lower manufacturing costs and higher sales volume.
On the bottom line, Rockwell Medical reported a net loss of $1.2 million in the second quarter of 2026. The loss was $1.5 million in the year-earlier quarter and $1.6 million in the first quarter of 2026. In the same period of 2026, the company generated $2.1 million in cash flow from operations. Its cash balance was $24.8 million on June 30, 2026. These figures provide prior financial context for the third-quarter announcement and do not replace its results.
The results took on added significance after the company announced on November 3 an agreement to acquire Vantive’s global kidney dialysis products and equipment business. Rockwell Medical estimated that the combined businesses would generate annual revenue of between $400 million and $450 million under its current assumptions. It set the base purchase price at $125 million. The deal financing includes two term loans of $50 million each, along with a $25 million convertible note. Vantive may also receive up to $45 million in additional contingent consideration tied to revenue and earnings before interest, taxes, depreciation and amortization milestones.
The company said the transaction is expected to close in mid-2027, subject to regulatory approvals and the satisfaction of closing conditions. It said there is no assurance the deal will close on the expected schedule or at all. Rockwell Medical develops, manufactures, markets and distributes kidney dialysis products to dialysis service providers worldwide. The company describes hemodialysis as the most common form of treatment for end-stage kidney disease. Chief Executive Mark Strobeck and Chief Financial Officer Jesse Neri are scheduled to discuss the third-quarter results, followed by a question-and-answer session.